18F-FEAC and 18F-FEDAC: PET of the Monkey Brain and Imaging of Translocator Protein (18 kDa) in the Infarcted Rat Brain

We evaluated two 18F-labeled PET ligands, N-benzyl-N-ethyl-2-[7,8-dihydro-7-(2-18F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide (18F-FEAC) and N-benzyl-N-methyl-2-[7,8-dihydro-7-(2-18F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide (18F-FEDAC), by investigating their kinetics in the monkey brain and by performing in vitro and in vivo imaging of translocator protein (18 kDa) (TSPO) in the infarcted rat brain. Methods: Dissection was used to determine the distribution of 18F-FEAC and 18F-FEDAC in mice, whereas PET was used for a monkey. With each 18F-ligand, in vitro autoradiography and small-animal PET were performed on infarcted rat brains. Results: 18F-FEAC and 18F-FEDAC had a high uptake of radioactivity in the heart, lung, and other TSPO-rich organs of mice. In vitro autoradiography showed that the binding of each 18F-ligand significantly increased on the ipsilateral side of rat brains, compared with the contralateral side. In a small-animal PET study, PET summation images showed the contrast of radioactivity between ipsilateral and contralateral sides. Pretreatment with TSPO ligands N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-9H-purin-9-yl)acetamide (AC-5216) or (R)-N-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide (PK11195) diminished the difference in uptake between the 2 sides. The PET study showed that each 18F-ligand had uptake and distribution patterns in the monkey brain similar to those of 11C-AC-5216. After injection into the monkey during PET, the uptake of each 18F-ligand in the brain decreased over time whereas 11C-AC-5216 did not. In the brain homogenate of mice, the percentage of the fraction corresponding to intact 18F-FEAC and 18F-FEDAC was 68% and 75% at 30 min after injection. In monkey plasma, each 18F-ligand was scarcely metabolized until the end of the PET scan. Conclusion: 18F-FEAC and 18F-FEDAC produced in vitro and in vivo signals allowing visualization of the increase in TSPO expression in the infarcted rat brain. The kinetics of both 18F-ligands in the monkey brain and tolerance for in vivo metabolism suggested their usefulness for imaging studies of TSPO in primates.

[1]  C. Braestrup,et al.  High densities of benzodiazepine receptors in human cortical areas , 1977, Nature.

[2]  C Crouzel,et al.  PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Abraham Weizman,et al.  Enigma of the peripheral benzodiazepine receptor. , 1999, Pharmacological reviews.

[4]  Tetsuya Suhara,et al.  [(11)C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. , 2003, Nuclear medicine and biology.

[5]  Tetsuya Suhara,et al.  Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. , 2004, Journal of medicinal chemistry.

[6]  Yuji Nagai,et al.  Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: An imaging tool for glial cells in the brain , 2004, Synapse.

[7]  D. Nutt,et al.  Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. , 2006, Trends in pharmacological sciences.

[8]  Ryuji Nakao,et al.  Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[10]  Tetsuya Suhara,et al.  Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor , 2007, Brain Research.

[11]  Jordi Llop,et al.  Imaging Brain Inflammation with [11C]PK11195 by PET and Induction of the Peripheral-Type Benzodiazepine Receptor after Transient Focal Ischemia in Rats , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  Jeih-San Liow,et al.  Radiation Dosimetry and Biodistribution in Monkey and Man of 11C-PBR28: A PET Radioligand to Image Inflammation , 2007, Journal of Nuclear Medicine.

[13]  Ryuji Nakao,et al.  Quantitative Analysis for Estimating Binding Potential of the Peripheral Benzodiazepine Receptor with [11C]DAA1106 , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  Denis Guilloteau,et al.  DPA-714, a New Translocator Protein–Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization , 2008, Journal of Nuclear Medicine.

[15]  Ming-Kai Chen,et al.  Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. , 2008, Pharmacology & therapeutics.

[16]  Makoto Sawada,et al.  Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies , 2008, The Journal of Neuroscience.

[17]  Hervé Boutin,et al.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  F. Yasuno,et al.  Increased Binding of Peripheral Benzodiazepine Receptor in Alzheimer's Disease Measured by Positron Emission Tomography with [11C]DAA1106 , 2008, Biological Psychiatry.

[19]  M. Grégoire,et al.  Synthesis and biological evaluation of substituted [18F]imidazo[1,2-a]pyridines and [18F]pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. , 2008, Journal of medicinal chemistry.

[20]  Michael Kassiou,et al.  Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. , 2009, Current medicinal chemistry.

[21]  Annelaure Damont,et al.  Comparative Evaluation of the Translocator Protein Radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a Rat Model of Acute Neuroinflammation , 2009, Journal of Nuclear Medicine.

[22]  M. Pomper,et al.  Initial Evaluation of 11C-DPA-713, a Novel TSPO PET Ligand, in Humans , 2009, Journal of Nuclear Medicine.

[23]  T. Guilarte,et al.  Translocator Protein 18kDA (TSPO): Molecular Sensor of Brain Injury & Repair , 2009 .

[24]  Kazutoshi Suzuki,et al.  [18F]FEAC and [18F]FEDAC: Two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain. , 2009, Bioorganic & medicinal chemistry letters.

[25]  Hidehiko Takahashi,et al.  Quantitative Analysis of Peripheral Benzodiazepine Receptor in the Human Brain Using PET with 11C-AC-5216 , 2009, Journal of Nuclear Medicine.

[26]  Yota Fujimura,et al.  Quantification of Translocator Protein (18 kDa) in the Human Brain with PET and a Novel Radioligand, 18F-PBR06 , 2009, Journal of Nuclear Medicine.

[27]  Annelaure Damont,et al.  Evaluation of the PBR/TSPO Radioligand [18F]DPA-714 in a Rat Model of Focal Cerebral Ischemia , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.